The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Genzyme (Inst); Genzyme (Inst); Hedera Dx (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); socar (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)
 
Christina S Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Guardant Health; Janssen; Pfizer; Regeneron; Silverback Therapeutics; Takeda; Turning Point Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Spectrum Pharmaceuticals (Inst); TP Therapeutics (Inst)
 
Melina Elpi Marmarelis
Stock and Other Ownership Interests - Bluebird Bio; Gilead Sciences; Johnson & Johnson; Merck; Pfizer; Portola Pharmaceuticals
Honoraria - AstraZeneca; Blueprint Medicines; Blueprint Medicines; Health Advances (I); Janssen Oncology; Novocure; Takeda; Targeted Oncology; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Ikena Oncology
Research Funding - AstraZeneca (Inst); Lilly (Inst); Trizell (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Novocure
 
Joshua K. Sabari
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Medscape; Navire; Pfizer; Regeneron; Takeda
 
Koichi Goto
Honoraria - Amgen; Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Life Technologies; Lilly Japan; Medpace; Merck; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace
Research Funding - Amgen (Inst); Amgen (Inst); Amgen Astellas BioPharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyowa Kirin Co., Ltd. (Inst); Lilly Japan (Inst); Loxo (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); NEC Corporation (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Dainippon Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Thermo Fisher Scientific (Inst); Turning Point Therapeutics (Inst)
 
Catherine A. Shu
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Genentech/Roche; Janssen; Mirati Therapeutics; Takeda
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Janssen (Inst)
 
Jong-Seok Lee
No Relationships to Disclose
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Elevation Oncology; Turning Point Therapeutics
Honoraria - ARIAD/Takeda; BeiGene; Caris Life Sciences; Daiichi Sankyo; Dava Oncology; Johnson & Johnson/Janssen; Lilly; Pfizer
Consulting or Advisory Role - BeiGene; Daiichi Sankyo; Elevation Oncology; Janssen; Lilly; Pfizer; Takeda
Speakers' Bureau - Caris Life Sciences
Research Funding - ARIAD (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen
Other Relationship - DAAN Biotherapeutics
 
Saiama Naheed Waqar
Research Funding - Abbvie (Inst); ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cullinan Pearl (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Ignyta (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Millennium (Inst); Newlink Genetics (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Roche (Inst); Verastem (Inst); Vertex (Inst); Xcovery (Inst)
 
Aurélie Swalduz
Honoraria - Amgen; AZD; Boehringer Ingelheim; Roche
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; Janssen; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Janssen
 
Pascale Tomasini
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Janssen; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Pfizer; Takeda
 
Joshua Michael Bauml
Employment - Janssen
 
Joshua C Curtin
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Songbai Wang
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Tim Jatkoe
Employment - Janssen Research & Development
 
Michael Gormley
Employment - Janssen Research & Development
 
Leonardo Trani
Employment - Janssen Research & Development
 
Roland Elmar Knoblauch
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson; Johnson & Johnson (I)
Travel, Accommodations, Expenses - Johnson & Johnson
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS